Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 μg and fluticasone propionate 250 μg: Implications for establishing bioequivalence of inhaled products
- 28 February 2009
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 31 (2), 370-385
- https://doi.org/10.1016/j.clinthera.2009.02.007
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Dry powder inhalers (DPIs)—A review of device reliability and innovationInternational Journal of Pharmaceutics, 2008
- In Vitro/In VivoComparisons in Pulmonary Drug DeliveryJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2008
- Studies of the Human Oropharyngeal Airspaces Using Magnetic Resonance Imaging IV—The Oropharyngeal Retention Effect for Four Inhalation Delivery SystemsJournal of Aerosol Medicine, 2007
- The DiskusTM: a review of its position among dry powder inhaler devicesInternational Journal of Clinical Practice, 2007
- Particle deposition measurements and numerical simulation in a highly idealized mouth–throatJournal of Aerosol Science, 2004
- Bioavailability of Orally Administered Micronised Fluticasone PropionateClinical Pharmacokinetics, 2000
- Particle Deposition in a Cast of Human Oral AirwaysAerosol Science and Technology, 1999
- Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography–tandem mass spectrometryJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- Impact of Oropharyngeal Deposition on Inhaled DoseJournal of Aerosol Medicine, 1998
- Trials to assess equivalence: the importance of rigorous methodsBMJ, 1996